JANX
Janux Therapeutics Inc
NASDAQ: JANX · HEALTHCARE · BIOTECHNOLOGY
$14.37
+1.84% today
Updated 2026-04-30
Market cap
$882.06M
P/E ratio
—
P/S ratio
88.21x
EPS (TTM)
$-1.83
Dividend yield
—
52W range
$12 – $35
Volume
1.0M
Janux Therapeutics Inc (JANX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $380000.00 | $3.64M | $8.61M | $8.08M | $10.59M | $10.00M |
| Revenue growth (YoY) | — | — | +857.1% | +136.8% | -6.1% | +31.0% | -5.6% |
| Cost of revenue | $6000.00 | $13000.00 | $36.57M | $75.70M | $1.96M | $2.06M | $2.03M |
| Gross profit | $-6000.00 | $-13000.00 | $3.64M | $8.61M | $6.13M | $8.53M | $7.97M |
| Gross margin | — | -3.4% | 100.0% | 100.0% | 75.8% | 80.5% | 79.7% |
| R&D | $3.00M | $3.04M | $26.24M | $53.44M | $54.92M | $68.39M | $125.90M |
| SG&A | $772000.00 | $1.80M | $10.33M | $22.26M | $26.14M | $41.05M | $41.77M |
| Operating income | $-3.77M | $-4.84M | $-32.93M | $-67.09M | $-72.98M | $-98.85M | $-157.67M |
| Operating margin | — | -1274.5% | -905.4% | -779.0% | -902.9% | -933.6% | -1576.7% |
| EBITDA | $-3.77M | $-6.57M | $-32.82M | $-66.25M | $-71.02M | $-96.79M | $-111.60M |
| EBITDA margin | — | -1727.6% | -902.3% | -769.3% | -878.7% | -914.1% | -1116.0% |
| EBIT | $-3.77M | $-6.58M | $-32.93M | $-67.09M | $-72.98M | $-98.85M | $-113.63M |
| Interest expense | $233000.00 | $206000.00 | $370000.00 | $4.03M | — | — | — |
| Income tax | $233000.00 | $-1.53M | $-113000.00 | $-8.90M | $1.79M | — | — |
| Effective tax rate | -5.8% | 18.4% | 0.3% | 14.1% | -3.2% | 0.0% | 0.0% |
| Net income | $-4.24M | $-6.78M | $-32.56M | $-54.15M | $-58.29M | $-68.99M | $-113.63M |
| Net income growth (YoY) | — | -60.1% | -379.9% | -66.3% | -7.6% | -18.4% | -64.7% |
| Profit margin | — | -1785.3% | -895.2% | -628.8% | -721.2% | -651.6% | -1136.3% |